News | January 12, 2023
Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
Positive opinions based on significant survival benefit
The only definitive way to diagnose and stage lung cancers is through biopsies
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Innate to receive $5M milestone payment from AstraZeneca
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Subscribe To Our Newsletter & Stay Updated
